- Home
- EDF vs ENTA Comparison
EDF vs ENTA Comparison
Compare EDF & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- ENTA
- Stock Information
- Founded
- EDF 2010
- ENTA 1995
- Country
- EDF United States
- ENTA United States
- Employees
- EDF N/A
- ENTA N/A
- Industry
- EDF Investment Managers
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- EDF Finance
- ENTA Health Care
- Exchange
- EDF Nasdaq
- ENTA Nasdaq
- Market Cap
- EDF 160.2M
- ENTA 164.6M
- IPO Year
- EDF N/A
- ENTA 2013
- Fundamental
- Price
- EDF $5.03
- ENTA $11.30
- Analyst Decision
- EDF
- ENTA Strong Buy
- Analyst Count
- EDF 0
- ENTA 6
- Target Price
- EDF N/A
- ENTA $20.83
- AVG Volume (30 Days)
- EDF 160.6K
- ENTA 1.5M
- Earning Date
- EDF 01-01-0001
- ENTA 11-24-2025
- Dividend Yield
- EDF 13.14%
- ENTA N/A
- EPS Growth
- EDF N/A
- ENTA N/A
- EPS
- EDF N/A
- ENTA N/A
- Revenue
- EDF N/A
- ENTA $64,806,000.00
- Revenue This Year
- EDF N/A
- ENTA $0.07
- Revenue Next Year
- EDF N/A
- ENTA N/A
- P/E Ratio
- EDF N/A
- ENTA N/A
- Revenue Growth
- EDF N/A
- ENTA N/A
- 52 Week Low
- EDF $3.51
- ENTA $4.09
- 52 Week High
- EDF $5.50
- ENTA $15.34
- Technical
- Relative Strength Index (RSI)
- EDF N/A
- ENTA 58.20
- Support Level
- EDF N/A
- ENTA $9.91
- Resistance Level
- EDF N/A
- ENTA $11.59
- Average True Range (ATR)
- EDF 0.00
- ENTA 1.50
- MACD
- EDF 0.00
- ENTA 0.21
- Stochastic Oscillator
- EDF 0.00
- ENTA 49.58
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.